556 Evaluating Important Change and Clearance of Disease Activity as Clinical Efficacy Measures for Clinical Trials in Dermatomyositis

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.632
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Evaluating Cognitive Outcome Measures for MS Clinical Trials: What Is a Clinically Meaningful Change?

Multiple Sclerosis
Neurology
2012English

Outcome Measures for Clinical Trials Assessing Treatment of Cystic Fibrosis Lung Disease

Clinical Investigation
2012English

Knowledge, Attitudes, and Self-Efficacy as Predictors of Preparedness for Oncology Clinical Trials

Medical Decision Making
Health Policy
2013English

Compositional Magnetic Resonance Imaging Measures of Cartilage — Endpoints for Clinical Trials of Disease-Modifying Osteoarthritis Drugs?

Journal of Rheumatology
RheumatologyAllergyImmunology
2016English

Adaptive Optics for Inherited Retinal Disease Clinical Trials

Acta Ophthalmologica
MedicineOphthalmology
2018English

Environmental Conditions Are Important for Establishing and Evaluating Pre-Clinical Models of GVHD

Bone Marrow Transplantation
TransplantationHematology
2011English

Clinical Trials for Multiple Sclerosis: Outcome Measures and Impact on Cognitive Function

Clinical and Experimental Neuroimmunology
NeuroscienceNeurologyImmunologyMicrobiology
2019English

Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases - A Systematic Review

Clinical Gastroenterology and Hepatology
HepatologyGastroenterology
2018English

Letting the Right One In: Evaluating the Generalisability of Clinical Trials

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy